The European Union's drug regulator said on Wednesday it could decide on Novavax's COVID-19 vaccine approval "within weeks" if the data it has received from the drugmaker was sufficient to prove the shot's effectiveness.
The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,